In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Switch in Time....

Executive Summary

The UK, already a leading player in Rx-to-OTC switches, recently adopted new legislation to encourage even more. The implication: companies' prescription and consumer divisions will have to work more closely throughout a product's life cycle to devise cohesive strategies for success in both markets.

You may also be interested in...



Schering-Plough's About-Face On OTC Claritin

Just ten months after telling the FDA that granting Claritin OTC status posed a "major health risk," Schering-Plough--threatened by the genericization of its blockbuster drug and possible OTC competitors on the horizon--has changed its tune and asked the agency to approve the switch. Its a move which may presage a sea change in drug marketing as pressure could mount for other NSAs, as well as medications in other therapeutic categories, to go non-prescription.

Senexis Ltd.

Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.

Working Around Pre-Emption Rights

Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.

Topics

Related Companies

UsernamePublicRestriction

Register

IV004569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel